AUTHORS
Alan Flores, PharmD, Rick Y. Lin, MD2, Dat Ngo, PharmD3, Ni-Chun Tsai4, Jose Tinajero, PharmD5, Yazeed Samara, MD6, Sunmin Park, MD PhD7, Salman Otoukesh, MD8, Hoda Pourhassan, MD9, Tamer Othman, MD10, Amanda Blackmon, DO11, Idoroenyi Amanam, MD12, Julio Alvarenga Thiebaud, MD13, Brian John Ball, MD, MS14, Paul Koller, MD15, Vaibhav Agrawal, MD16, Amandeep Salhotra, MD17, Karamjeet Singh Sandhu, MD18, Samer Khaled, MD19, Ahmed Aribi, MD20, Ibrahim Aldoss, MD21, Haris Ali, MD22, Vinod Pullarkat, MD23, Andrew Artz, MD,MS24, Anthony Selwyn Stein, MD25, Stephen J. Forman, MD26, Guido Marcucci, MD27, Ryotaro Nakamura, MD28, Monzr M. M Al Malki, MD29
AFFILIATIONS
1 City of Hope, Duarte, California, United States
2 City of Hope, Duarte, California, United States
3 City of Hope, Duarte, California, United States
4 City of Hope, Duarte, California, United States
5 City of Hope, Duarte, California, United States
6 City of Hope, Duarte, California, United States
7 City of Hope, Duarte, California, United States
8 City of Hope, Duarte, California, United States
9 City of Hope, Duarte, California, United States
10 City of Hope, Duarte, California, United States
11 City of Hope, Duarte, California, United States
12 City of Hope, Duarte, California, United States
13 City of Hope, Duarte, California, United States
14 City of Hope, Duarte, California, United States
15 City of Hope, Duarte, California, United States
16 City of Hope, Duarte, California, United States
17 City of Hope, Duarte, California, United States
18 City of Hope, Duarte, California, United States
19 City of Hope, Duarte, California, United States
20 City of Hope, Duarte, California, United States
21 City of Hope, Duarte, California, United States
22 City of Hope, Duarte, California, United States
23 City of Hope, Duarte, California, United States
24 City of Hope, Duarte, California, United States
25 City of Hope, Duarte, California, United States
26 City of Hope, Duarte, California, United States
27 City of Hope, Duarte, California, United States
28 City of Hope, Duarte, California, United States
29 City of Hope, Duarte, California, United States
ABSTRACT
Background
Post-transplant cyclophosphamide (PTCy) has become a cornerstone of allogeneic hematopoietic cell transplantation (allo-HCT) by improving transplant outcomes through effective graft-versus-host disease (GvHD) prevention. Hemorrhagic cystitis (HC) is a major complication associated with the administration of PTCy and strategies such as the use of intravenous hyperhydration have been routinely employed to minimize this risk (Mac et al. BMT 2021). Although effective, the use of hyperhydration often leads to fluid overload (FO), specifically in older patients, and those with worse renal or cardiac function (Samuels et al. Front Immunol. 2025). Herein, we describe a risk adoption model where high-risk patients undergoing allo-HCT with PTCy undergo a novel preventative continuous bladder irrigation (CBI). This study aims to characterize the efficacy of CBI as an alternative to hyperhydration in preventing HC in those at risk of FO.
Methods
Retrospective chart review was conducted on patients with malignant hematological diseases who received their first allo-HCT regardless of conditioning regimen intensity or donor at City of Hope National Medical Center from June 2019 to June 2023 and received PTCy as part of their GvHD prophylactic regimen. Since 2019, patients undergoing allo-HCT with PTCy with one or more high risk criteria (age greater than 70 years, poor renal function (pre-HCT creatinine clearance of 60 ml/min or less), or history of cardiovascular disease (congestive heart failure or coronary artery disease) received prophylactic CBI starting 4 hours before the first dose of PTCy until 24 hours after the second dose instead of hyperhydration. CBI recipients also received mesna and intravenous hydration at a low rate. HC was assessed via daily urinalysis following PTCy administration as well as patient-reported symptoms relating to HC. Viruria within the first 100 days of transplant was also recorded with a particular focus on pathogens known to cause HC such as BK virus, adenovirus, CMV, and HHV6. Viral-associated HC was defined by a positive viral presence in urine, and chemical HC was defined by no positive viral presence in urine. Grade 3 and 4 FO (Grade 3 = FO involving 1 organ, Grade 4 = ICU admission or FO involving 2 or more organs) was defined using criteria adapted from a previously published study assessing fluid overload with hyperhydration with PTCy.
Results
A total of 64 patients with median age of 73 (range 44-82) received PTCy with CBI as HC prophylaxis. Most of the study population was male (57.8%, n=37). Patients most frequently underwent allo-HCT for acute myeloid leukemia (51.6%, n=33), followed by myeloproliferative neoplasms/myelofibrosis (18.8%, n=12) and myelodysplastic syndrome (17.2%, n=11). The most common indications for CBI were age > 70 years (64.1%, n=41), history of renal dysfunction (42.1%, n=27), and history of cardiovascular dysfunction (34.3%, n=22). Conditioning was myeloablative in 5 patients (7.8%) and reduced-intensity in 59 (92.2%). The most common regimens were fludarabine/melphalan (37.5%, n=24) and cyclophosphamide/fludarabine/total body irradiation (35.9%, n=23). Donors were unrelated in 62.5% (n=40), haploidentical in 31.3% (n=20), and matched siblings in 6.3% (n=4). In addition to PTCy and mycophenolate, 60.9% (n=39) of patients received sirolimus and 39.1% (n=25) received tacrolimus as GvHD prophylaxis.
The overall incidence of HC was 50% (n=32) with no grade 3 or 4 events. The median onset of HC was 3 days (range 3-66) and the median duration was 8 days (range 1-99). 13 (40.6%) of these patients had viral-associated HC due to BK virus. In addition, 35.9% (n=23) of patients had subclinical HC that was related to foley catheter insertion (negative urinalysis within 7 days and asymptomatic). Symptomatic HC was reported in 25% (n=16) of patients with 18.8% (n=12) requiring medical intervention, including phenazopyridine (50%, n=6), platelet transfusions (50%, n=6), and oxybutynin (16.7%, n=2). Nine patients (14.1%) developed grade 3 or 4 FO between days 3 to 8.
Conclusions
In our cohort, a risk assessment approach providing CBI as HC prevention with PTCy in high-risk patients was safe and effective in preventing higher grade HC while limiting grades 3-4 FO during days 3-8 (PTCy hyperhydration period). Comparative analyses against high-risk patients receiving standard hyperhydration are ongoing to validate these findings.
DISCLOSURES
Alan Flores, PharmD: No relevant conflicts of interest to declare.